help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reaven, G. M.
Right arrow Articles by Jaspan, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reaven, G. M.
Right arrow Articles by Jaspan, J. B.

Journal of Clinical Endocrinology & Metabolism, Vol 64, 106-110, Copyright © 1987 by Endocrine Society

ARTICLES

Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus

GM Reaven, YD Chen, A Golay, AL Swislocki and JB Jaspan

Plasma glucose, insulin, FFA, glucagon, and GH concentrations were measured over an 8-h period in normal subjects and patients with noninsulin-dependent diabetes mellitus (NIDDM). Meals were consumed at 0800 h (20% of daily calories) and noon (40% of daily calories), and measurements were made hourly from 0800-1600 h. Day-long plasma glucose, insulin, and FFA concentrations were higher than normal (by two-way analysis of variance) in patients with NIDDM, whether obese or nonobese. In addition, day-long plasma glucagon concentrations were also higher than normal (by two-way analysis of variance) in both nonobese and obese patients with NIDDM. Furthermore, direct relationships were found between the total plasma glucagon response from 0800-1600 h and total plasma glucose (r = 0.57; P less than 0.001) and FFA (r = 0.30; P less than 0.06) responses. In contrast, plasma GH levels were not increased in patients with NIDDM. These data demonstrate that ambient plasma concentrations of both glucose and FFA are higher in patients with NIDDM, despite the fact that coexisting plasma insulin levels are equal to or higher than normal. The higher day-long plasma glucagon levels in patients with NIDDM may contribute to their higher plasma glucose and FFA concentrations.


This article has been cited by other articles:


Home page
 EndocrinologyHome page
V. Singh, C. Grotzinger, K. W. Nowak, S. Zacharias, E. Goncz, G. Pless, I. M. Sauer, I. Eichhorn, B. Pfeiffer-Guglielmi, B. Hamprecht, et al.
Somatostatin Receptor Subtype-2-Deficient Mice with Diet-Induced Obesity Have Hyperglycemia, Nonfasting Hyperglucagonemia, and Decreased Hepatic Glycogen Deposition
Endocrinology, August 1, 2007; 148(8): 3887 - 3899.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. E. Dunning and J. E. Gerich
The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Endocr. Rev., May 1, 2007; 28(3): 253 - 283.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Abdul-Ghani and R. A. DeFronzo
Fasting Hyperglycemia Impairs Glucose- But Not Insulin-Mediated Suppression of Glucagon Secretion
J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1778 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
J. Gromada, I. Franklin, and C. B. Wollheim
{alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
Endocr. Rev., February 1, 2007; 28(1): 84 - 116.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Sorensen, M. S. Winzell, C. L. Brand, K. Fosgerau, R. W. Gelling, E. Nishimura, and B. Ahren
Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired {beta}-Cell Function
Diabetes, December 1, 2006; 55(12): 3463 - 3469.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
J. Girard
The Inhibitory Effects of Insulin on Hepatic Glucose Production Are Both Direct and Indirect
Diabetes, December 1, 2006; 55(Supplement_2): S65 - S69.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
H. Sorensen, C. L. Brand, S. Neschen, J. J. Holst, K. Fosgerau, E. Nishimura, and G. I. Shulman
Immunoneutralization of Endogenous Glucagon Reduces Hepatic Glucose Output and Improves Long-Term Glycemic Control in Diabetic ob/ob Mice.
Diabetes, October 1, 2006; 55(10): 2843 - 2848.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
M. Z. Strowski, D. E. Cashen, E. T. Birzin, L. Yang, V. Singh, T. M. Jacks, K. W. Nowak, S. P. Rohrer, A. A. Patchett, R. G. Smith, et al.
Antidiabetic Activity of a Highly Potent and Selective Nonpeptide Somatostatin Receptor Subtype-2 Agonist
Endocrinology, October 1, 2006; 147(10): 4664 - 4673.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
X. C. Li, O. A. Carretero, Y. Shao, and J. L. Zhuo
Glucagon Receptor-Mediated Extracellular Signal-Regulated Kinase 1/2 Phosphorylation in Rat Mesangial Cells: Role of Protein Kinase A and Phospholipase C
Hypertension, March 1, 2006; 47(3): 580 - 585.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. Eid, S. Bodin, B. Ferrier, H. Delage, M. Boghossian, M. Martin, G. Baverel, and A. Conjard
Intrinsic Gluconeogenesis Is Enhanced in Renal Proximal Tubules of Zucker Diabetic Fatty Rats
J. Am. Soc. Nephrol., February 1, 2006; 17(2): 398 - 405.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
D. A. Elder, R. L. Prigeon, R. P. Wadwa, L. M. Dolan, and D. A. D'Alessio
{beta}-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults
J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 185 - 191.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. Raju and P. E. Cryer
Maintenance of the postabsorptive plasma glucose concentration: insulin or insulin plus glucagon?
Am J Physiol Endocrinol Metab, August 1, 2005; 289(2): E181 - E186.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
K. Dungan and J. B. Buse
Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
Clin. Diabetes, April 1, 2005; 23(2): 56 - 62.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S. A. Qureshi, M. Rios Candelore, D. Xie, X. Yang, L. M. Tota, V. D.-H. Ding, Z. Li, A. Bansal, C. Miller, S. M. Cohen, et al.
A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Diabetes, December 1, 2004; 53(12): 3267 - 3273.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Zander, A. Christiansen, S. Madsbad, and J. Juul Holst
Additive Effects of Glucagon-Like Peptide 1 and Pioglitazone in Patients With Type 2 Diabetes
Diabetes Care, August 1, 2004; 27(8): 1910 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. B. Degn, C. B. Juhl, J. Sturis, G. Jakobsen, B. Brock, V. Chandramouli, J. Rungby, B. R. Landau, and O. Schmitz
One Week's Treatment With the Long-Acting Glucagon-Like Peptide 1 Derivative Liraglutide (NN2211) Markedly Improves 24-h Glycemia and {alpha}- and {beta}-Cell Function and Reduces Endogenous Glucose Release in Patients with Type 2 Diabetes
Diabetes, May 1, 2004; 53(5): 1187 - 1194.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
T. Ostergard, K. B. Degn, M.-A. Gall, R. D. Carr, J. D. Veldhuis, M. K. Thomsen, R. A. Rizza, and O. Schmitz
The Insulin Secretagogues Glibenclamide and Repaglinide Do Not Influence Growth Hormone Secretion in Humans but Stimulate Glucagon Secretion during Profound Insulin Deficiency
J. Clin. Endocrinol. Metab., January 1, 2004; 89(1): 297 - 302.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
O. G. Kolterman, J. B. Buse, M. S. Fineman, E. Gaines, S. Heintz, T. A. Bicsak, K. Taylor, D. Kim, M. Aisporna, Y. Wang, et al.
Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes
J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3082 - 3089.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
B. Ahren and O. Thorsson
Increased Insulin Sensitivity Is Associated with Reduced Insulin and Glucagon Secretion and Increased Insulin Clearance in Man
J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1264 - 1270.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Guldstrand, B. Ahren, and U. Adamson
Improved beta -cell function after standardized weight reduction in severely obese subjects
Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E557 - E565.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Coll. Nutr.Home page
J. Hallfrisch, D. J. Scholfield, and K. M. Behall
Glucose and Insulin Responses to a New Zero-Energy Fiber Source
J. Am. Coll. Nutr., October 1, 2002; 21(5): 410 - 415.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. L. Kjems, B. M. Kirby, E. M. Welsh, J. D. Veldhuis, M. Straume, S. S. McIntyre, D. Yang, P. Lefebvre, and P. C. Butler
Decrease in {beta}-Cell Mass Leads to Impaired Pulsatile Insulin Secretion, Reduced Postprandial Hepatic Insulin Clearance, and Relative Hyperglucagonemia in the Minipig
Diabetes, September 1, 2001; 50(9): 2001 - 2012.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
C. H. Gravholt, N. Møller, M. D. Jensen, J. S. Christiansen, and O. Schmitz
Physiological Levels of Glucagon Do Not Influence Lipolysis in Abdominal Adipose Tissue as Assessed by Microdialysis
J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2085 - 2089.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
V. Umpaichitra, W. Bastian, D. Taha, M. A. Banerji, T. W. AvRuskin, and S. Castells
C-peptide and Glucagon Profiles in Minority Children with Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1605 - 1609.
[Abstract] [Full Text]

Home page
 J. Clin. Endocrinol. Metab.Home page
P. Shah, A. Vella, A. Basu, R. Basu, W. F. Schwenk, and R. A. Rizza
Lack of Suppression of Glucagon Contributes to Postprandial Hyperglycemia in Subjects with Type 2 Diabetes Mellitus
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4053 - 4059.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1987 by The Endocrine Society